• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

WHO CEWG process: Identification of Health R&D Demonstration Projects

3 Dec 2013

WHO Member States from every regions are currently going through a selection process of “demonstration projects” in order to provide evidences on innovative mechanisms to fund and coordinate public health R&D to address unmet medical needs of developing countries and to contribute to further discussion on a sustainable global framework as recommended by the Expert Working Group on Financing and Coordination (CEWG).

DNDi has been involved in the overall CEWG process. Specifically, DNDi has submitted two candidate demonstration projects with the aim to demonstrate that projects can be optimized through guiding principles such as cross-regional collaboration of existing networks, open-innovation and knowledge sharing, equitable access to new products, and sustainable funding secured through existing and new funding mechanisms. DNDi is also partner in another candidate demonstration project, on cutaneous leishmaniasis, submitted by the US Food and Drug Administration and Osaka University.

On December 3-4 2013, after weeks of consultations, MSs and experts assessed 22 proposals for the identification of health R&D Demonstration Projects, and finally selected 7+1 projects – including DNDi and partners’ project on Visceral Leishmaniasis.

At the end of the December meeting, MSs requested that the secretariat seek further elaboration from the original proposers of the 7+1 short-listed proposals on innovative aspects of their projects, and that the so-called “addendum” were reviewed  at the 134th meeting of the WHO Executive Board (EB) on January 20-25 January 2014.

Summaries of the 7+1 proposals as well as addendum submitted to the WHO Secretariat

Finally, as the outcome of the EB, Members Sates requested the WHO secretariat to “consider the demonstration projects in the order listed (..) and taking into account the additional information received with the participation of the Chair and Vice-Chair of the CEWG, as appropriate start convening virtual or direct meetings with stakeholders interested in funding and/or implementing the projects (…)”. Report of these initial steps will be released at the World Health Assembly for further consideration.

  • Viewpoint
  • Briefing Summary


Read more about the DNDi demonstration project on the WHO website:

  • The Visceral Leishmanisis (VL) Global R&D & Access Initiative

Projects submitted by DNDi and its partners

  • The Visceral Leishmaniasis (VL) Global R&D & Access Initiative (Submitted and selected)
  • Addendum to the “The Visceral Leishmaniasis (VL) Global R&D & Access Initiative” project
  • Chagas R&D Accelerator Initiative: A Coordination Mechanism For Accelerating The Development Of New Health Tools For Chagas Disease (Submitted)
Policy advocacy Funding Visceral leishmaniasis

Read, watch, share

Loading...
Press releases
8 Jul 2026

Brazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of India

Patricia, 44, from Area 44 in Lilongwe, Malawi, has lived with vision loss for 10 years following a late diagnosis of cryptococcal meningitis.
Stories
30 Jun 2026

Cryptococcal meningitis: Africa’s neglected HIV killer

News
29 Jun 2026

Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors 

Publications
29 Jun 2026

Advancing global health innovation through Europe-Africa collaboration

Mamadou Diop senior health technician - biologist at CERPAD Lab at Gaston Berger University
Stories
17 Jun 2026

The DNDi-MMV Joint Regulatory Platform: ‘a pioneering programme project for non-profit medical research organizations to speak with one voice’

MASAMUNA, DR CONGO, JANUARY 2026: The mother superior of the nuns who run the local clinic is also the lab technican.
Press releases
12 Jun 2026

DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness

Statements
9 Jun 2026

DNDi Statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)

Press releases
8 Jun 2026

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license